Vincristine, Doxorubicin, Cyclophosfamide, Actinomycin D, Ifosfamide, and Etoposide in Adult and Pediatric Patients with Nonmetastatic Ewing Sarcoma. Final Results of a Monoinstitutional Study
| Autor: | Enza Barbieri, Massimo Eraldo Abate, Stefano Ferrari, Alba Balladelli, Gaetano Bacci, Alessandra Longhi, Emanuela Palmerini, Mario Mercuri, Laura Cantero, Marco Alberghini, Eric L. Staals, Piero Picci, Marilena Cesari |
|---|---|
| Přispěvatelé: | Ferrari S, Palmerini E, Alberghini M, Staals EL, Mercuri M, Barbieri E, Longhi A, Cantero L, Cesari M, Abate M, Balladelli A, Picci P, Bacci G. |
| Rok vydání: | 2010 |
| Předmět: |
Adult
Male Oncology Cancer Research medicine.medical_specialty Vincristine Necrosis Adolescent medicine.medical_treatment Bone Neoplasms Sarcoma Ewing 030218 nuclear medicine & medical imaging 03 medical and health sciences 0302 clinical medicine Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Doxorubicin Ifosfamide Child Cyclophosphamide Chemotherapy toxicity Etoposide Chemotherapy business.industry General Medicine Middle Aged Necrosi medicine.disease Treatment Outcome Child Preschool 030220 oncology & carcinogenesis Toxicity Dactinomycin Female Sarcoma medicine.symptom business Ewing sarcoma medicine.drug |
| Zdroj: | Scopus-Elsevier Europe PubMed Central Alma Mater Studiorum Università di Bologna-IRIS |
| ISSN: | 2038-2529 0300-8916 |
| DOI: | 10.1177/030089161009600205 |
| Popis: | Aims and backgroundTo investigate a six-drug combination in patients with non-metastatic Ewing sarcoma, focusing on chemotherapy-induced necrosis and chemotherapy toxicity in adult and pediatric patients.Methods and study designAlternating cycles of vincristine (1.5 mg/m2), doxorubicin (80 mg/m2) and cyclophosfamide (1200 mg/m2) (weeks 0, 6, 13, 22a nd 31), ifosfamide (9 g/m2), vincristine (1.5 mg/m2), and actinomycin D (1.5 mg/m2) (weeks 3, 16, 25 and 34), and ifosfamide (9 g/m2) and etoposide (450 mg/m2) (weeks 9, 19, 28 and 37) were administered. Primary chemotherapy-induced necrosis was graded: G3 (complete necrosis), G2 (microfoci of tumor cells) and G1 (macrofoci of tumor cells).ResultsFrom 1996 to 1999, 50 patients with Ewing sarcoma were enrolled. The median age was 23.5 years (range, 4–56). Chemotherapy-induced necrosis (in 28 patients) was G3 in 36%, G2 in 21% and G1 in 43%. At a median follow-up of 110 months (range, 36–129), 5-year overall survival and event-free survival were 72% and 66%, respectively. According to histologic response, 5-year event-free survival was 90% in G3, 83% in G2, and 42% in G1 (P = 0.02). In adult and pediatric (ConclusionsThe six-drug combination can be administered safely in adult and pediatric populations. About 40% of patients have a poor chemotherapy-induced tumor necrosis, leading to poor probability of survival. New strategies are recommended to improve survival of poor responders to the six-drug combination. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|